Navigation Links
FDA Approves Strativa Pharmaceuticals' Zuplenz® (ondansetron) Oral Soluble Film
Date:7/2/2010

WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Zuplenz® (ondansetron) oral soluble film for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.  Zuplenz, a unique formulation of ondansetron, is the first oral soluble film approved by the FDA as a prescription medication.

The FDA approval was granted based on clinical study data comparing the bioequivalence of Zuplenz 8 mg to Zofran ODT® (orally dissolving tablet) 8 mg.  The pharmacokinetic results of these studies demonstrated that a single dose of Zuplenz, taken with or without water and under fed and fasting conditions, was comparable to Zofran ODT.

"The FDA approval of Zuplenz marks an important milestone for Strativa as it reinforces our commitment to enhancing prescription products to meet the different needs of patients," said John A. MacPhee, President, Strativa Pharmaceuticals. "Zuplenz offers an innovative and convenient, easy-to-take formulation for patients who have trouble swallowing tablets, while providing the trusted efficacy expected from ondansetron."

Zuplenz uses proprietary PharmFilm® oral soluble film technology from MonoSol Rx to rapidly dissolve on the tongue without the need for water, which can cause additional discomfort for some patients suffering from nausea and vomiting.  Zuplenz will be offered in 4 mg and 8 mg dosage strengths, and is expected to be available in retail pharmacies in the third quarter of 2010.

Nausea and vomiting is a common side effect associated with chemotherapy, radiotherapy, and surgery. Left untreated, nausea and
'/>"/>

SOURCE Strativa Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 Fuse Science, Inc. (OTCQB: ... company that is developing new, patent-pending technologies poised to redefine ... that it will hold a business update teleconference and webcast ... nd , 2013 at 4:30 PM ET. ... will host the call and will be joined by ...
(Date:5/17/2013)... May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... Kyle Guse , Chief Financial Officer & General ... Conference on Thursday, May 30, 2013, in New ... The Company,s presentation is scheduled to begin at ... webcast. To access the webcast, go to www.atossagenetics.com . ...
(Date:5/17/2013)... 2013 Sinovac Biotech Ltd. (Nasdaq: SVA ... , today announced that it will release its unaudited ... before market on Tuesday, May 28, 2013.  The Company will ... 8:00 a.m. EDT (May 28, 2013 at 8:00 p.m. China ... an update on recent corporate developments. To access ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 2Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results 3
(Date:5/18/2013)... (May 18, 2013) The use of a ... colonoscopy, according to new research presented today at ... begins days in advance of the procedure, includes ... to be taken at strict intervals. The better ... to see cancer and precancerous polyps in the ...
(Date:5/18/2013)... ground-breaking advance in colonoscopy technology signals the future ... at Digestive Disease Week (DDW). Additional research focuses ... and exploring safer methods for removing polyps. ... called a colonoscope to examine the colon. This ... to look for precancerous polyps called adenomas in ...
(Date:5/18/2013)... The “World Healthcare IT Market: Trends & Forecast (2010 ... restraints, and opportunities in North America, Europe, Asia, & ... 89 market data tables , ... , http://www.marketsandmarkets.com/Market-Reports/healthcare-information-technology-market-136.html , Early buyers ... healthcare IT market is expected to grow from $99.6 ...
(Date:5/18/2013)... KY (PRWEB) May 18, 2013 During ... hearing loss should consider the legal protections they have, ... when problems arise with their child’s treatment or hearing ... , Since 1927, the American Speech-Language-Hearing Association has used ... disorders and to promote treatment, such as cochlear implants, ...
(Date:5/18/2013)... Adolescents, especially young males, who experiment ... “K2” are landing in emergency rooms across America. ... epidemic with a new treatment program for those ... research from the National Institute on Drug Abuse, synthetic ... American teenagers. In 2012, 11 percent of high school ...
Breaking Medicine News(10 mins):Health News:New smartphone application improves colonoscopy preparation 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 2Health News:Healthcare IT Market to reach US$ 162.2 Billion by 2015 at a CAGR of 10.2% - New Report by MarketandMarkets 3Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 2Health News:Schachter, Hendy & Johnson PSC Lawyer Says Cochlear Implant Victims Should Know Their Legal Rights 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2
... The supervisory board of Celesio AG has today approved ... wholesaler Panpharma. This step into one of the most ... Celesio,s growth strategy. Celesio doesn,t plan to setup a ... about two years thoroughly analysing the Brazilian pharmaceutical market, ...
... mental stress not seen in those with high blood pressure, ... and other forms of mental stress cause dilation of the ... brain in healthy people, but this doesn,t occur in those ... researchers who used ultrasound imaging to monitor the carotid arteries ...
... , SACRAMENTO, Calif., July 10 After several months ... the chief executive officer of a leading statewide mental ... shop Psycho Donuts, will meet face to face to ... questionable business practices. , , Owners Kipp Berdiansky ...
... Aegis of Granada Hills has been named "Best Assisted Living ... their annual Readers Choice Awards. This is the second year in ... award. In voting, Aegis was a write-in candidate and received ... metro area to gain top status. , , ...
... 10 A sometimes fatal "superbug" is popping up in ... people live. It,s called methicillin-resistant Staphylococcus aureus, (MRSA "mer,-sa"). Health ... to slow its spread. , , "Physicians, health ... threat through the appropriate use of antibiotics, proper wound care ...
... more than half of patients reported improvement , FRIDAY, July ... asthma and other respiratory conditions shows promise in restoring a ... ability. , "More work needs to be done but, for ... an option worth trying," said Dr. Ronald Kuppersmith, clinical assistant ...
Cached Medicine News:Health News:Celesio Acquires Majority Stake in Number One Brazilian Pharmaceutical Wholesaler Panpharma 2Health News:Blood Rush to the Brain When Angry Is a Good Sign 2Health News:There Is No Way to Sugar Coat These Donuts 2Health News:Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer 'Superbug' 2Health News:Blue Cross and Blue Shield of Illinois Urges Constant Vigilance Against Growing Threat of Killer 'Superbug' 3Health News:Drug Might Restore Sense of Smell 2Health News:Drug Might Restore Sense of Smell 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: